HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reinhard Dummer Selected Research

Exanthema (Rash)

12/2023Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
11/2023First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
11/2022Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
1/2021Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
4/2015Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
3/2014Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
3/2013MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
7/2012Improved survival with MEK inhibition in BRAF-mutated melanoma.
1/2012Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
6/2011Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Reinhard Dummer Research Topics

Disease

329Melanoma (Melanoma, Malignant)
04/2024 - 03/2002
219Neoplasms (Cancer)
04/2024 - 01/2002
57Neoplasm Metastasis (Metastasis)
03/2024 - 05/2002
29Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
12/2021 - 03/2002
25Basal Cell Carcinoma (Rodent Ulcer)
10/2023 - 10/2003
19Disease Progression
01/2023 - 01/2004
18Skin Neoplasms (Skin Cancer)
04/2024 - 01/2002
18Lymphoma (Lymphomas)
01/2023 - 01/2002
17Brain Neoplasms (Brain Tumor)
11/2022 - 02/2008
12Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2023 - 08/2008
11Dermatitis
12/2023 - 09/2011
11Mycosis Fungoides
12/2021 - 01/2003
11Carcinogenesis
01/2021 - 08/2004
10Exanthema (Rash)
12/2023 - 06/2011
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2023 - 05/2004
7Uveal melanoma
05/2024 - 01/2018
7Colitis
08/2020 - 05/2015
7B-Cell Lymphoma (Lymphoma, B Cell)
01/2020 - 01/2002
6Testicular Neoplasms (Testicular Cancer)
10/2020 - 01/2007
6Lymphatic Metastasis
01/2019 - 08/2003
5Pruritus (Itching)
12/2023 - 01/2021
5Fever (Fevers)
12/2023 - 09/2017
5Wounds and Injuries (Trauma)
01/2023 - 12/2011
5Inflammation (Inflammations)
01/2022 - 01/2009
5Neutropenia
11/2018 - 07/2013
5Fatigue
09/2017 - 07/2008
4Nausea
11/2023 - 06/2011
4Hypertension (High Blood Pressure)
11/2022 - 01/2017
4Residual Neoplasm
11/2022 - 03/2015
4Pain (Aches)
12/2021 - 03/2002
4Alopecia (Baldness)
01/2020 - 06/2011

Drug/Important Bio-Agent (IBA)

60Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
04/2024 - 12/2009
50Immune Checkpoint InhibitorsIBA
03/2024 - 06/2017
44IpilimumabIBA
12/2023 - 01/2013
38Proteins (Proteins, Gene)FDA Link
01/2024 - 01/2002
31Biomarkers (Surrogate Marker)IBA
01/2024 - 01/2006
29VemurafenibIBA
04/2024 - 06/2011
28pembrolizumabIBA
03/2024 - 08/2015
26NivolumabIBA
10/2023 - 07/2015
21binimetinibIBA
04/2024 - 03/2013
21AntigensIBA
08/2023 - 01/2002
21InterferonsIBA
01/2022 - 03/2002
18encorafenibIBA
04/2024 - 01/2015
17AntibodiesIBA
01/2024 - 09/2002
17Dacarbazine (DIC)FDA LinkGeneric
12/2023 - 12/2005
17CytokinesIBA
11/2023 - 03/2002
17Phosphotransferases (Kinase)IBA
10/2023 - 12/2009
17trametinibIBA
01/2022 - 07/2012
16dabrafenibIBA
01/2022 - 01/2015
15LigandsIBA
11/2023 - 03/2002
14Imiquimod (Aldara)FDA LinkGeneric
01/2023 - 01/2003
13RNA (Ribonucleic Acid)IBA
04/2024 - 07/2003
13sonidegibIBA
06/2023 - 04/2014
11Peptides (Polypeptides)IBA
12/2021 - 05/2002
10Messenger RNA (mRNA)IBA
01/2023 - 03/2002
10Mitogen-Activated Protein KinasesIBA
03/2019 - 12/2009
9DNA (Deoxyribonucleic Acid)IBA
01/2022 - 06/2002
9Interleukin-2 (IL2)IBA
09/2019 - 03/2002
8Monophenol Monooxygenase (Tyrosinase)IBA
01/2024 - 01/2004
8Formaldehyde (Formol)FDA Link
01/2021 - 04/2004
8MART-1 AntigenIBA
01/2019 - 01/2004
7L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
12/2023 - 12/2007
7talimogene laherparepvecIBA
10/2023 - 01/2017
7Monoclonal AntibodiesIBA
01/2020 - 04/2004
7Interferon-alpha (Interferon Alfa)IBA
08/2012 - 08/2003
6EnzymesIBA
11/2023 - 07/2005
6HhAntag691IBA
05/2022 - 06/2015
6Bexarotene (LGD1069)FDA Link
12/2021 - 08/2006
6Temozolomide (Temodar)FDA LinkGeneric
01/2018 - 12/2005
6OligonucleotidesIBA
11/2012 - 03/2002
6HLA-G Antigens (HLA G)IBA
02/2008 - 01/2002
5tebentafuspIBA
12/2023 - 01/2021
5HLA-A Antigens (HLA-A)IBA
12/2023 - 05/2002
5T-Cell Antigen Receptors (T-Cell Receptor)IBA
12/2023 - 07/2004
5Glycoproteins (Glycoprotein)IBA
12/2023 - 05/2013
5cobimetinibIBA
12/2023 - 01/2015
5spartalizumabIBA
11/2023 - 10/2020
5Transcription Factors (Transcription Factor)IBA
11/2023 - 08/2012
5MicroRNAs (MicroRNA)IBA
11/2023 - 11/2019
5MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA
01/2023 - 02/2010
5Programmed Cell Death 1 ReceptorIBA
01/2022 - 09/2015
5Brentuximab VedotinIBA
12/2021 - 01/2015
5Adapalene (Differin)FDA LinkGeneric
12/2021 - 04/2011
5ParaffinIBA
01/2021 - 04/2004
5Differentiation AntigensIBA
08/2020 - 12/2006
5HLA Antigens (Human Leukocyte Antigens)IBA
01/2020 - 03/2002
5Creatine Kinase (Creatine Phosphokinase)IBA
01/2019 - 03/2013
5Proto-Oncogene Proteins B-rafIBA
01/2018 - 06/2011
5Interleukin-10 (Interleukin 10)IBA
01/2016 - 01/2002
4atezolizumabIBA
12/2023 - 01/2022
4B7-H1 AntigenIBA
01/2023 - 09/2017

Therapy/Procedure

195Therapeutics
03/2024 - 01/2002
78Immunotherapy
04/2024 - 01/2002
26Drug Therapy (Chemotherapy)
01/2023 - 03/2002
22Radiotherapy
11/2023 - 12/2003
12Aftercare (After-Treatment)
05/2023 - 10/2003
7Lasers (Laser)
01/2020 - 11/2003
5Injections
12/2022 - 03/2002
5Lymph Node Excision (Lymph Node Dissection)
01/2022 - 02/2008
4Precision Medicine
01/2021 - 03/2014